NASDAQ:AVRO AVROBIO (AVRO) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.38▼$1.4450-Day Range$1.40▼$18.2452-Week Range$0.88▼$1.65Volume206,800 shsAverage Volume269,831 shsMarket Capitalization$62.85 millionP/E Ratio2.03Dividend YieldN/APrice Target$24.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get AVROBIO alerts: Email Address AVROBIO MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,614.3% Upside$24.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$587,190 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.48) to ($0.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.77 out of 5 starsMedical Sector460th out of 936 stocksBiological Products, Except Diagnostic Industry68th out of 154 stocks 3.0 Analyst's Opinion Consensus RatingAVROBIO has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAVROBIO has received no research coverage in the past 90 days.Read more about AVROBIO's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AVRO. Previous Next 0.0 Dividend Strength Dividend YieldAVROBIO does not currently pay a dividend.Dividend GrowthAVROBIO does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVRO. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows2 people have added AVROBIO to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AVROBIO insiders have bought more of their company's stock than they have sold. Specifically, they have bought $587,190.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.20% of the stock of AVROBIO is held by insiders.Percentage Held by Institutions62.63% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AVROBIO's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for AVROBIO are expected to grow in the coming year, from ($0.48) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AVROBIO is 2.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of AVROBIO is 2.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Book Value per Share RatioAVROBIO has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about AVROBIO's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About AVROBIO Stock (NASDAQ:AVRO)AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. AVRO Stock News HeadlinesJune 20, 2024 | investorplace.comWhy Is Avrobio (AVRO) Stock Moving Today?June 3, 2024 | businesswire.comTectonic Therapeutic Appoints Daniel Lochner as Chief Financial OfficerJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 16, 2024 | finance.yahoo.comAVROBIO, Inc. (AVRO) Stock Price, News, Quote & History - Yahoo FinanceMay 15, 2024 | fr.investing.comUn cadre d'Avrobio achète des actions d'une valeur de plus de 970 000 dollarsMay 9, 2024 | businesswire.comAVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVROApril 22, 2024 | bizjournals.comDeal watch: Biopharma M&A more than doubled in Q1March 26, 2024 | wsj.comAVROBIO Inc.July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.February 23, 2024 | ca.finance.yahoo.comAVRO Apr 2024 2.500 callFebruary 18, 2024 | finance.yahoo.comAVRO May 2024 2.500 callFebruary 14, 2024 | businesswire.comAVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVROJanuary 31, 2024 | stockhouse.comShareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with TectonicJanuary 31, 2024 | bizjournals.comFive things: Vertex's new drug, a reverse merger, and how are you doing?January 31, 2024 | msn.comAvrobio Inc Announces Executive Team Changes and AppointmentsJanuary 30, 2024 | bizjournals.comAvrobio to take Watertown biotech public via reverse mergerJanuary 30, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCALJanuary 30, 2024 | msn.comAvrobio to buy 100% equity interests of Tectonic TherapeuticSee More Headlines Receive AVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AVRO CUSIPN/A CIK1681087 Webwww.avrobio.com Phone(617) 914-8420FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$24.00 High Stock Price Target$24.00 Low Stock Price Target$24.00 Potential Upside/Downside+1,614.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.69 Trailing P/E Ratio2.03 Forward P/E RatioN/A P/E GrowthN/ANet Income$12.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.52% Return on Assets-47.13% Debt Debt-to-Equity RatioN/A Current Ratio26.17 Quick Ratio26.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book0.66Miscellaneous Outstanding Shares44,890,000Free Float40,764,000Market Cap$62.85 million OptionableOptionable Beta1.23 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Erik John Ostrowski M.B.A. (Age 52)President, Interim CEO, CFO & Treasurer Comp: $1.25MDr. Azadeh Golipour Ph.D. (Age 44)Chief Technology Officer Comp: $1.01MDr. Essra Ridha FFPM (Age 41)M.D., Chief Medical Officer Comp: $1.12MMr. Jeffrey Medin Ph.D.Scientific FounderMr. Steven N. Avruch J.D. (Age 62)Chief Legal Officer & Secretary Comp: $506.68kMr. Scott GottesmanVice President of Human ResourceMs. Kirsten DupuisChief of StaffMore ExecutivesKey CompetitorsFreeline TherapeuticsNASDAQ:FRLNZura BioNASDAQ:ZURAMolecular PartnersNASDAQ:MOLNMonte Rosa TherapeuticsNASDAQ:GLUECaribou BiosciencesNASDAQ:CRBUView All CompetitorsInsiders & InstitutionsIkarian Capital LLCBought 35,802 shares on 5/17/2024Ownership: 1.680%Affinity Asset Advisors LLCBought 200,000 shares on 5/15/2024Ownership: 1.559%Braden Michael LeonardBought 39,146 shares on 5/13/2024Total: $587,190.00 ($15.00/share)Vanguard Group Inc.Bought 279,400 shares on 5/10/2024Ownership: 4.193%Acadian Asset Management LLCSold 217,526 shares on 5/10/2024Ownership: 2.757%View All Insider TransactionsView All Institutional Transactions AVRO Stock Analysis - Frequently Asked Questions How were AVROBIO's earnings last quarter? AVROBIO, Inc. (NASDAQ:AVRO) issued its earnings results on Thursday, May, 9th. The company reported ($1.80) earnings per share for the quarter. When did AVROBIO's stock split? AVROBIO shares reverse split before market open on Thursday, June 20th 2024. The 1-12 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did AVROBIO IPO? AVROBIO (AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager. What other stocks do shareholders of AVROBIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven (BHVN) and Nabriva Therapeutics (NBRV). This page (NASDAQ:AVRO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVROBIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AVROBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
